ArticleEuropean journal of nuclear medicine and molecular imaging2025
Artificial intelligence-enabled opportunistic identification of immune checkpoint inhibitor-related adverse events using [
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management.Frontiers in immunology · 2026Review
- Review
- Synthetic imaging for research and education in nuclear medicine: Who's afraid of the black box?European journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmune checkpoint inhibitors (ICI) have transformed cancer therapy, improving outcomes in malignancies like lung cancer, melanoma, and lymphoma by targeting PD-1, PD-L1, and CTLA-4 to enhance T cell-mediated tumor destruction. However, ICI often induce immune-related adverse events (irAEs) across multiple organs. [18F]FDG PET/CT is a valuable tool for assessing immune activation, but whole-organ inflammation evaluation remains time-consuming and prone to variability. This study investigates AI-driven organ-level [18F]FDG PET/CT uptake changes pre- and post-ICI therapy to opportunistically detect irAEs.
methodsA total of 64 patients with lung cancer, melanoma, or lymphoma who underwent [18F]FDG PET/CT before and after ICI therapy were included. Automated delineation of anatomical structures was performed using an artificial intelligence approach involving multiple subsequently applied deep learning models. SUVmax and SUVmean were quantified for irAE-related organs (thyroid, myocardium, pancreas, liver, bone, spleen, and adrenal glands) after automated tumor lesion removal. Statistical analysis identified uptake changes linked to clinically observed inflammation-related adverse events.
resultsAmong 64 patients (mean scan interval 4.5 months), thyroid uptake increased post-ICI (ΔSUVmax=0.44, p = 0.04; ΔSUVmean=0.22, p = 0.08). Increased uptake occurred in 55% (SUVmax) and 53% (SUVmean) of patients. Thyroid-related adverse events were more frequent in those with increased uptake (29% vs. 3%, p = 0.008), with uptake increase being the most pronounced in the cases of hypothyroidism (p = 0.002 for SUVmax, p = 0.03 for SUVmean). Myocardial, pancreatic, and hepatic uptake increased but without statistical significance (p > 0.05).
conclusionAI-enabled opportunistic [18F]FDG PET/CT screening effectively detects thyroid-related irAEs, particularly hypothyroidism, through uptake quantification. This approach offers a promising biomarker for early irAE detection, enhancing patient management and immunotherapy optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.